The new Bio Ventures III fund lifts Arkin Bio’s assets under management above $600 million and will target early-stage biotech companies worldwide developing treatments for cancer, rare diseases and other high unmet medical needs| Read More ynet – Business | Read More in Virtual Jerusalem. in Israel NOWlej.
